VS38 as a promising CD38 substitute antibody for flow cytometric detection of plasma cells in the daratumumab era-Reference-Cited by-同舟云学术

VS38 as a promising CD38 substitute antibody for flow cytometric detection of plasma cells in the daratumumab era

Published:2019-06-10 Issue:3 Volume:110 Page:322-330
ISSN:0925-5710
Container-title:International Journal of Hematology
language:en
Short-container-title:Int J Hematol

Author:

Mizuta Shumpei^ORCID,Kawata Takahito,Kawabata Hiroshi,Yamane Noriko,Mononobe Saya,Komai Takao,Koba Yusuke,Ukyo Naoya,Tamekane Akira,Watanabe Mitsumasa

Publisher

Springer Science and Business Media LLC

Subject

Hematology

Link

http://link.springer.com/content/pdf/10.1007/s12185-019-02685-z.pdf

Reference22 articles.

1. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364:1046–60.

2. Paiva B, Vidriales MB, Cerveró J, Mateo G, Pérez JJ, Montalbán MA, et al. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood. 2008;112:4017–23.

3. Rawstron AC, Child JA, de Tute RM, Davies FE, Gregory WM, Bell SE, et al. Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study. J Clin Oncol. 2013;31:2540–7.

4. Flores-Montero J, Sanoja-Flores L, Paiva B, Puig N, García-Sánchez O, Böttcher S, et al. Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia. 2017;31:2094–103.

5. Paiva B, van Dongen JJ, Orfao A. New criteria for response assessment: role of minimal residual disease in multiple myeloma. Blood. 2015;125:3059–68.

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Circulating plasma cells as a predictive biomarker in Multiple myeloma: an updated systematic review and meta-analysis;Annals of Medicine;2024-04-10

2. Diagnostic Flow Cytometry in the Era of Targeted Therapies;Surgical Pathology Clinics;2023-06

3. Mature B‐ and plasma‐cell flow cytometric analysis: A review of the impact of targeted therapy;Cytometry Part B: Clinical Cytometry;2022-11-02

4. CD38-specific nanobodies allow in vivo imaging of multiple myeloma under daratumumab therapy;Frontiers in Immunology;2022-10-27

5. Minimal Residual Disease in Multiple Myeloma—Current Approaches and Future Clinical Implications;Hemato;2022-07-19